Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study - PubMed (original) (raw)

Clinical Trial

Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study

B J Lange et al. Med Pediatr Oncol. 1996 Jul.

Abstract

Methotrexate (MTX) infusions of 500--1,000 mg/m2 over 24 hours may improve survival and prevent relapse in children with acute lymphoblastic leukemia (ALL). Childrens Cancer Group (CCG) Study 139 compared weekly oral methotrexate 20 mg/m2/week (oral MTX) to MTX 500 mg/m2 infused over 24 hours (IV MTX) three times during consolidation and every 6 weeks during maintenance in 164 children with intermediate-risk ALL, i.e., those patients over age 1 year with white blood cell count 10,000 to 49,999/ml and no bulky extramedullary disease. Median follow-up for CCG-139 exceeded 75 months. Thirty-four events occurred among 80 patients receiving IV and oral MTX and 36 events among 84 patients receiving oral MTX. Two children died during induction and one did not enter remission. Remission induction rate is 98%. There have been 26 marrow relapses, 11 combined marrow and extramedullary relapses, 24 CNS relapses, and five testicular or other relapses. The frequency and distribution of relapses does not differ between the two regimens. For the entire group, overall event-free survival (EFS) at 6 years is 57.9% (standard deviation=4.0%) and actuarial survival is 80.0% (standard deviation =3.3%). Of the 29 patients with isolated extramedullary relapse, 18 survive free of a second event, a median of 42 months from relapse. In contrast to other trials, this trial does not show that IV MTX in this dose and schedule offers an advantage over standard therapy for this group of children.

PubMed Disclaimer

Similar articles

• [Results and experiences with a modified BFM protocol for treatment of recurrences in children with acute lymphoblastic leukemia in East German areas].
  Sauerbrey A, Zintl F, Malke H, Reimann M, Maaser M, Domula M, Dörffel W, Eggers G, Exadaktylos P, Kotte W, et al. Sauerbrey A, et al. Klin Padiatr. 1993 Jul-Aug;205(4):281-7. doi: 10.1055/s-2007-1025238. Klin Padiatr. 1993. PMID: 8377448 Clinical Trial. German.
• Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
  Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi A, Miniero R, Di Tullio MT, Lo Nigro L, Pession A, Rondelli R, Messina C, Santoro N, Mori PG, De Rossi G, Tamaro P, Silvestri D, Biondi A, Basso G, Masera G. Conter V, et al. Haematologica. 1998 Sep;83(9):791-9. Haematologica. 1998. PMID: 9825576 Clinical Trial.
• [Intensification of the initial treatment in acute lymphoblastic leukemias of middle and high risk in children].
  Ortega Aramburu JJ, Javier Manchón G, Olivé Oliveras T, Montagut Dueso JM, Acebedo Lerzundi G, Torán Fuentes N. Ortega Aramburu JJ, et al. An Esp Pediatr. 1989 Feb;30(2):109-15. An Esp Pediatr. 1989. PMID: 2655513 Review. Spanish.
• Acute lymphoblastic leukaemia in a child with cystic fibrosis.
  Rizzari C, Conter V, Jankovic M, D'Angelo P, Masera G, Costantini D, Bettinelli ME, Giunta AM. Rizzari C, et al. Haematologica. 1992 Sep-Oct;77(5):427-9. Haematologica. 1992. PMID: 1483594 Review.

Cited by

• Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review.
  Hsieh CH, Huang YW, Tsai TF. Hsieh CH, et al. Dermatol Ther (Heidelb). 2022 Apr;12(4):835-860. doi: 10.1007/s13555-022-00713-1. Epub 2022 Apr 5. Dermatol Ther (Heidelb). 2022. PMID: 35381976 Free PMC article. Review.
• Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia.
  Richards S, Pui CH, Gayon P; Childhood Acute Lymphoblastic Leukemia Collaborative Group (CALLCG). Richards S, et al. Pediatr Blood Cancer. 2013 Feb;60(2):185-95. doi: 10.1002/pbc.24228. Epub 2012 Jun 12. Pediatr Blood Cancer. 2013. PMID: 22693038 Free PMC article. Review.
• Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.
  Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, La M, Gastier-Foster JM, Heerema NA, Sailer S, Buckley PJ, Thomson B, Cole C, Nachman JB, Reaman G, Winick N, Carroll WL, Devidas M, Gaynon PS. Matloub Y, et al. Blood. 2011 Jul 14;118(2):243-51. doi: 10.1182/blood-2010-12-322909. Epub 2011 May 11. Blood. 2011. PMID: 21562038 Free PMC article. Clinical Trial.
• Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.
  Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, Hunger SP, Devidas M; Children's Oncology Group. Gaynon PS, et al. Leukemia. 2010 Feb;24(2):285-97. doi: 10.1038/leu.2009.262. Epub 2009 Dec 17. Leukemia. 2010. PMID: 20016531 Free PMC article. Clinical Trial.
• Oral cancer chemotherapy in paediatric patients: obstacles and potential for development and utilisation.
  Bleyer WA, Danielson MG. Bleyer WA, et al. Drugs. 1999;58 Suppl 3:133-40. doi: 10.2165/00003495-199958003-00018. Drugs. 1999. PMID: 10711852 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley